Company: CERO
Filing Date: 2025-07-14
Form Type: 424B3
Source: 0001213900-25-063764
Chunk: 4

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-14
Form: 424B3
Chunk 4
---
 (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                                                                         |     | Trading Symbol(s) |     | Name of each exchange on which registered |
| Common stock, par value $0.0001 per share                                                   |     | CERO              |     | NASDAQ Global Market                      |
| Warrants, each whole warrant exercisable for one two-thousandths of a share of common stock |     | CEROW             |     | NASDAQ Capital Market                     |

Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

As previously disclosed, CERo Therapeutics Holdings,
Inc., a Delaware corporation (the “Company”) and an institutional investor (the “Investor”) entered into a common
stock purchase agreement on each of February 14, 2024 (the “February Purchase Agreement”) and November 8, 2024 (the “November
Purchase Agreement” and, collectively, the “Prior Purchase Agreements”), pursuant to which, upon the terms and subject
to the conditions and limitations set forth in such Prior Purchase Agreements, the Company may issue and sell to the Investor up to an
aggregate of $25.0 million of the Company’s outstanding common stock, par value $0.0001 per share (the “Common Stock”).
As of June 30, 2025, the Company has issued and sold (i) 11,689 shares of Common Stock for aggregate proceeds of approximately $4.4 million
pursuant to the February Purchase Agreement, and (ii) 100,584 shares of Common Stock for aggregate proceeds of approximately $3.1 million
pursuant to the November Purchase Agreement. Accordingly, in order to enable the Company to